1. Archdeacon P, Grandinetti C, Vega JM, Balderson D, Kramer JM. Optimizing expedited safety reporting for drugs and biologics subject to an investigational new drug application. Therapeutic Innovation & Regulatory Science 2014;48(2):200–207.
2. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER) & Center for Biologics Evaluation and Research (CBER). Guidance for industry and investigators, safety reporting requirements for INDs and BA/BE studies. https://www.fda.gov/downloads/Drugs/Guidances/UCM227351.pdf. Published December 2012. Accessed September 20, 2017.
3. Perez R, Archdeacon P, Roach N, et al. Sponsors’ and investigative staffs’ perceptions of the current investigational new drug safety reporting process in oncology trials. Clin Trials. 2017;14(3):225–233.
4. Jarow JP, Casak S, Chuk M, Ehrlich LA, Khozin S. The majority of expedited investigational new drug safety reports are uninformative. Clin Cancer Res. 2016;22(9):2111–2113.
5. US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER) & Center for Biologics Evaluation and Research (CBER). Safety assessment for IND safety reporting guidance for industry draft guidance. https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM477584.pdf. Published December 2015. Accessed September 20, 2017.